Figure 2. OS comparisons of anti-EGFR and anti-VEGF therapies in addition to chemotherapy regimens FOLFIRI or FOLFOX as compared to chemotherapy alone as first-line treatment for advanced or metastatic colorectal cancer.

(A) and (C) Chemotherapy regimen comparison for all-RAS and KRAS WT. (B) and (D) Mutation status comparison for all-RAS and KRAS. Treatments are compared to chemotherapy alone. Bayesian network estimates reported as hazard ratio (95% credible intervals in black and 95% predictive intervals in red). *Probability that the treatment arm is better than chemotherapy alone.